• Visit the USI website
  • Go back to the homepage

Institute for Research in Biomedicine
Istituto di Ricerca in Biomedicina

Via Vincenzo Vela 6 - CH-6500 Bellinzona
Tel. +41 91 820 0300 - Fax +41 91 820 0302 - info [at] irb [dot] usi [dot] ch

TargetIng novel MEchanisms of Resolution in inflammation (TIMER)

Hosting organisation:

Fondazione Humanitas per la Ricerca
Via Manzoni 56, Rozzano, Italy

Coordinator: Alberto Mantovani
IRB Participants:
  • Mariagrazia Uguccioni, Group Leader, Vice Director
  • Research area:

    HEALTH.2011.1.4-5 New therapeutic approaches in chronic inflammatory and autoimmune diseases

    Duration: 01.01.2012 to 31.12.2015
    Website: http://www.eumbrella.org

    Resolution of inflammation is a key determinant of pathology, and an active process which involves diverse pathways and molecules. The general objective of the TIMER Consortium is to identify and validate new molecules involved in the resolution of inflammation as a basis for the development of innovative therapeutic strategies in chronic inflammatory and autoimmune diseases. The project will involve discovery of new natural or synthetic pro-resolving molecules for plant and animals and investigation on endogenous inflammation pro-resolving mechanisms identified by various partners of the Consortium, including atypical chemokine receptors, decoy receptors, and microRNA. Tapping resources of natural compounds will be a major thrust.

    Efforts will be mainly focused on the regulation by pro-resolving agents on two molecular systems of key relevance in inflammation: the chemokine system, which regulates recruitment, permanence and egress of leukocyte in tissues; and the TLR/IL-1R system, which is central for the activation of infiltrating leukocytes., To this purpose, the project will capitalize on, and bring added value to a strong tradition of the Consortium in the fields of: leukocyte recruitment and activation; negative regulators of inflammation; industrial-academic collaboration; identification and characterization of innovative inhibitors of natural origin; European-Brazilian collaboration.